Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis

Overview

Journal Curr Pharmacol Rep

Date 2017 Oct 7

PMID 28983452

Citations 47

Authors

Laura E Armstrong

Grace L Guo

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: About 15-25% of patients with simple steatosis of non-alcoholic fatty liver disease progresses to non-alcoholic steatohepatitis (NASH), and the underlying mechanism for this progression has not been elucidated. NASH ultimately could progress to cirrhosis, an irreversible condition.

Recent Findings: Farnesoid X receptor (FXR) has been studied for its role in modulating inflammation, and the expression of FXR is down-regulated during NASH development. FXR deficiency has shown to progress and exacerbate NASH development, and FXR activation has been protective against liver inflammation associated with NASH. The expression of factors in both the adaptive and innate immune response in the liver are regulated in a FXR-dependent and -independent manner.

Summary: Therefore, understanding key signaling pathways of liver inflammation in NASH is important to determine essential components that predispose, progress, or exacerbate NASH. FXR has been identified as a therapeutic target for NASH to prevent liver inflammation.

Citing Articles

Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy.

Wang Y, Yang L, Xu Q, Liu T, He H, Liu L Pharmaceutics. 2025; 17(1).

PMID: 39861681 PMC: 11768695. DOI: 10.3390/pharmaceutics17010032.

Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.

Qi Y, Ma Y, Duan G Int J Mol Sci. 2025; 25(24.

PMID: 39769418 PMC: 11727972. DOI: 10.3390/ijms252413656.

Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy.

Fang Y, Qin M, Zheng Q, Wang K, Han X, Yang Q Kidney Int Rep. 2024; 9(11):3116-3133.

PMID: 39534198 PMC: 11551060. DOI: 10.1016/j.ekir.2024.08.002.

New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease.

Zhang J, Li Y, Yang L, Ma N, Qian S, Chen Y Cell Biosci. 2024; 14(1):90.

PMID: 38971765 PMC: 11227172. DOI: 10.1186/s13578-024-01267-9.

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.

Meroni M, Longo M, Dongiovanni P Front Endocrinol (Lausanne). 2024; 15:1411706.

PMID: 38846491 PMC: 11153718. DOI: 10.3389/fendo.2024.1411706.

References

Zhang S, Liu Q, Wang J, Harnish D . Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009; 379(2):476-9. DOI: 10.1016/j.bbrc.2008.12.117. View

Suzuki K, Lareyre J, Sanchez D, Gutierrez G, Araki Y, Matusik R . Molecular evolution of epididymal lipocalin genes localized on mouse chromosome 2. Gene. 2004; 339:49-59. DOI: 10.1016/j.gene.2004.06.027. View

Haukeland J, Damas J, Konopski Z, Loberg E, Haaland T, Goverud I . Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6):1167-74. DOI: 10.1016/j.jhep.2006.02.011. View

Cai Y, Jogasuria A, Yin H, Xu M, Hu X, Wang J . The Detrimental Role Played by Lipocalin-2 in Alcoholic Fatty Liver in Mice. Am J Pathol. 2016; 186(9):2417-28. PMC: 5012462. DOI: 10.1016/j.ajpath.2016.05.006. View

Wang Y, Chen W, Wang M, Yu D, Forman B, Huang W . Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48(5):1632-43. PMC: 3056574. DOI: 10.1002/hep.22519. View

Ganz M, Szabo G . Immune and inflammatory pathways in NASH. Hepatol Int. 2014; 7 Suppl 2:771-81. PMC: 3918407. DOI: 10.1007/s12072-013-9468-6. View

Ganz M, Bukong T, Csak T, Saha B, Park J, Ambade A . Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med. 2015; 13:193. PMC: 4467677. DOI: 10.1186/s12967-015-0552-7. View

Li L, Zhang Q, Peng J, Jiang C, Zhang Y, Shen L . Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage. Biochem Biophys Res Commun. 2015; 467(4):841-6. DOI: 10.1016/j.bbrc.2015.10.056. View

Zhan L, Liu H, Fang Y, Kong B, He Y, Zhong X . Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes. PLoS One. 2014; 9(9):e105930. PMC: 4157742. DOI: 10.1371/journal.pone.0105930. View

10.

Daly C, Rollins B . Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation. 2003; 10(3-4):247-57. DOI: 10.1038/sj.mn.7800190. View

11.

Wang Y, Fang W, Wei J, Wang T, Wang N, Ma J . The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice. J Chin Med Assoc. 2013; 76(12):686-92. DOI: 10.1016/j.jcma.2013.08.010. View

12.

Miura K, Yang L, van Rooijen N, Brenner D, Ohnishi H, Seki E . Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology. 2012; 57(2):577-89. PMC: 3566276. DOI: 10.1002/hep.26081. View

13.

Leroux A, Ferrere G, Godie V, Cailleux F, Renoud M, Gaudin F . Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012; 57(1):141-9. DOI: 10.1016/j.jhep.2012.02.028. View

14.

Manley S, Ding W . Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015; 5(2):158-67. PMC: 4629219. DOI: 10.1016/j.apsb.2014.12.011. View

15.

Meli R, Raso G, Calignano A . Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014; 5:177. PMC: 4005965. DOI: 10.3389/fimmu.2014.00177. View

16.

Sutti S, Bruzzi S, Albano E . The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update. Expert Rev Gastroenterol Hepatol. 2015; 10(2):243-53. DOI: 10.1586/17474124.2016.1111758. View

17.

Bieghs V, Trautwein C . The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013; 34(9):446-52. DOI: 10.1016/j.it.2013.04.005. View

18.

Goodwin B, Jones S, Price R, Watson M, McKee D, Moore L . A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000; 6(3):517-26. DOI: 10.1016/s1097-2765(00)00051-4. View

19.

Matsubara T, Li F, Gonzalez F . FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2012; 368(1-2):17-29. PMC: 3491147. DOI: 10.1016/j.mce.2012.05.004. View

20.

Ndumele C, Nasir K, Conceicao R, Carvalho J, Blumenthal R, Santos R . Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(8):1927-32. PMC: 3148106. DOI: 10.1161/ATVBAHA.111.228262. View